An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
GlycoMimetics to Participate at Upcoming Jefferies 2022 Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
GlycoMimetics, Inc. (NASDAQ: GLYC) will participate in the Jefferies 2022 Healthcare Conference on June 8 in New York, NY. CEO Harout Semerjian and CFO Brian Hahn will attend, with a fireside chat hosted by Research Analyst Roger Song, M.D. The chat will be available for 30 days on the GlycoMimetics website starting June 8 at approximately 3:30 p.m. ET. GlycoMimetics is a clinical-stage biotechnology company focused on developing glycobiology-based therapies for cancers and inflammatory diseases, aiming to create transformative treatments.
Positive
None.
Negative
None.
ROCKVILLE, Md.--(BUSINESS WIRE)--
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the Company will participate at the Jefferies 2022 Healthcare Conference, on June 8th, in New York, NY.
Chief Executive Officer Harout Semerjian and Chief Financial Officer Brian Hahn will attend in person. Research Analyst Roger Song, M.D. will host a fireside chat with Mr. Semerjian. An archived recording of the chat will be available for thirty days on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations, beginning Wednesday, June 8 at approximately 3:30 p.m. ET.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company’s science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. GlycoMimetics is located in Rockville, Maryland in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
